For the Inventor, By the Inventor

Enter assignee name

Marseilles, France

Innate Pharma, S.a.

USPTO Granted Patents = 18

CIPO Patents = 1

EPO Patents = 4

Trademarks = 1

Forward Citations = 160

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Alessandro Moretta (9 out of 21 patents)

Francois Romagne (7 out of 12 patents)

Pascale Andre (5 out of 18 patents)

4. Andrea Velardi (3 out of 4 patents)

5. Laurent Gauthier (2 out of 41 patents)

6. Mathieu Blery (2 out of 14 patents)

7. Christian Belmant (2 out of 14 patents)

8. Emanuela Marcenaro (2 out of 2 patents)

9. Mariella Della Chiesa (2 out of 6 patents)

10. Roberta Castriconi (2 out of 2 patents)

11. Christina Bottino (2 out of 2 patents)

12. Lorenzo Moretta (2 out of 4 patents)

13. Roberto Biassoni (2 out of 6 patents)

14. Cristina Bottino (2 out of 5 patents)

15. Ivan Perrot (1 out of 8 patents)

18 patents: Sort by Forward Citations

1. 10577416 - Mica binding agents (2020-03-03),

2. 10160810 - Monoclonal antibodies against NKG2A (2018-12-25),

3. 10059765 - Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds (2018-08-28),

4. 9902936 - PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy (2018-02-27),

5. 9844593 - Methods for treatment of recurrent hematological malignancies (2017-12-19),

6. 9447185 - Compositions and methods for treating proliferative disorders (2016-09-20),

7. 9090876 - Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds (2015-07-28),

8. 9067997 - Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders (2015-06-30),

9. 8993319 - Monoclonal antibodies against NKG2A (2015-03-31),

10. 8637258 - Compositions and methods for regulating NK cell activity (2014-01-28),

11. 8465931 - Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor (2013-06-18),

12. 8017596 - Phosphonates useful as modulators of T-γ-9-δ-2 activity (2011-09-13),

13. 7803376 - Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds (2010-09-28),

14. 7767842 - Class of γδ T cells activators and use thereof (2010-08-03),

15. 7732131 - Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor (2010-06-08),

Innate Pharma, S.A. is a biotechnology company specialized in the discovery and development of innovative therapeutic antibodies targeting the innate immune system to fight cancer and inflammatory diseases. With a focus on natural killer (NK) cell-based immunotherapies, Innate Pharma aims to unlock the potential of the immune system to overcome major medical challenges. By leveraging its proprietary technology and expertise, the company advances a diversified pipeline of first-in-class potential treatments. Innate Pharma is committed to transforming the lives of patients through groundbreaking immunotherapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

18 Patents

#4 in Marseilles

#1,074 in France

#33,199 in the World

Marseilles, France

Innate Pharma, S.a.

Forward Citations = 160

28 inventors:

Alessandro Moretta (9 out of 21 patents)

Francois Romagne (7 out of 12 patents)

Pascale Andre (5 out of 18 patents)

4. Andrea Velardi (3 out of 4 patents)

5. Laurent Gauthier (2 out of 41 patents)

Please report any incorrect information to support@idiyas.com

Loading…